Phase 2b Clinical Data on Treatment of Dry Eye, Presented at ARVO Annual Meeting

May 2024

The Association for Research into Vision and Ophthalmology held its annual scientific congress in Seattle from May 5-9. At the meeting, Penny Asbell, an internationally recognised expert in dry eye disease, and an investigator in the study, made the first presentation of the clinical trial results.

In the predefined sub-group with severe dry eye, subjects treated with 0.3% Pimecrolimus Suspension showed a statistically significant improvement in both corneal staining and ocular discomfort compared to vehicle control.

The results were well received and on the back of the interest generated, Premark continues to pursue options for a collaboration that will enable the completion of a Phase 3 programme and subsequent commercialisation of Pimecrolimus Suspension for the treatment of dry eye.

A Novel Ocular Formulation of Pimecrolimus for Treatment of Dry Eye